Science academique
2026
Kenneth Blum, Kai-Uwe Lewandrowski, Morgan P Lorio et al.
The aim of this perspective article is to evaluate the potential of Psychedelics in the management of Alcohol Use Disorder (AUD) vis-a-vis pre-existing therapeutic modalities and to elucidate practical directions for policy in AUD Addiction medicine, supported by scientific evidence, while prioritizing safety and accessibility. We performed a narrative synthesis of past and current literature...
Journal of Music Therapy
2026
Clare O’callaghan, Voula Kallianis, Margaret Ross
Limited evidence supports treatment for distress in life-threatening illness. Psychedelic-assisted psychotherapy (PAP) may help. Despite music's presence in PAP, sparse accounts of music-related experiences exist. Such research is needed to optimize music's presence within PAP. This qualitative analysis aimed to understand participants' music-related accounts of their PAP experiences within a...
International Journal of Drug Policy
2026
Christina Chwyl, Adrianne R Wilson-Poe, Kim Hoffman et al.
3 citations
There remain significant gaps in knowledge about best practices for facilitated psychedelic care and psychedelic-assisted therapy. To inform the development of service models that support safe and beneficial experiences, this qualitative study explored expert perspectives on current and ideal standards of care, including key practices (e.g., screening, adapting care to diverse contexts) and...
Neuroscience & Biobehavioral Reviews
2026
Netta Pinhas, Nofar Eidlman, Avigail Barnea et al.
2 citations
Microdosing - the practice of consuming extremely low doses of classical psychedelic substances that do not elicit overt psychedelic effects - has gained significant attention as a potential method for enhancing cognitive performance. However, findings from controlled studies remain mixed and inconclusive. This preregistered meta-analysis examined the cognitive effects of classical psychedelic...
Cureus
2026
Mohsin Raza, Jasleen Kaur
Psychedelic-assisted therapies have re-emerged as a subject of increasing scientific and clinical interest in psychiatry, particularly in the context of persistent treatment gaps for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. Compounds, including psilocybin and 3,4-methylenedioxymethamphetamine, are being evaluated in...
Advances in experimental medicine and biology
2026
Berend Olivier, Jocelien D A Olivier
Major depressive disorder (MDD), including treatment-resistant depression (TRD), is a highly prevalent psychiatric disorder. MDD is associated with severe suffering, burden and large economical costs. Although various conventional antidepressant treatments are available, a large portion of depressed people does not or not adequately respond to the first-line treatments (mostly SSRIs and SNRIs)...
Frontiers in Psychiatry
2026
Sofia Abramsky-Sze, Elliot Marseille, Richard Matzopoulos et al.
correction
[This corrects the article DOI: 10.3389/fpsyt.2025.1508811.].
Therapeutic Advances in Psychopharmacology
2026
Kristian Beichmann, Polina Catzeflis, Helena Aicher et al.
The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-N-methamphetamine (MDMA). The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH)....
Global Advances in Integrative Medicine and Health
2026
Haley D M Schuman, Raèf Mina, Sofia Barkova et al.
Healthcare providers' (HCPs) perspectives on psychedelic-assisted therapy (PAT) are critical to clinical integration but remain underexplored in Canadian palliative and oncology contexts. This study examines HCP attitudes toward ketamine, psilocybin, and MDMA, and the systemic and ethical factors influencing implementation. An exploratory qualitative study using semi-structured interviews was...
Medicinska istrazivanja
2026
Stefan Jerotić, Olga Čolović, Nađa Marić
Psychedelic-assisted psychotherapy (PAP) is emerging as a novel intervention for major psychiatric disorders, most notably major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). While psychotherapy is widely regarded as a core element of PAP its precise role remains poorly defined. This narrative review traces the development of PAP within contemporary Western psychiatry,...